432763.fig.001a
(a)
432763.fig.001b
(b)
432763.fig.001c
(c)
432763.fig.001d
(d)
432763.fig.001e
(e)
432763.fig.001f
(f)
432763.fig.001g
(g)
432763.fig.001h
(h)
432763.fig.001i
(i)
432763.fig.001j
(j)
432763.fig.001k
(k)
432763.fig.001l
(l)
432763.fig.001m
(m)
432763.fig.001n
(n)
432763.fig.001o
(o)
432763.fig.001p
(p)
432763.fig.001q
(q)
432763.fig.001r
(r)
432763.fig.001s
(s)
432763.fig.001t
(t)
Figure 1: Immunophenotypic profiles of mammary carcinomas in benign-mixed tumors of female dogs’ mammary gland: Canis familiaris. (a)–(d) ER staining; (e)–(h) PR staining; (i)–(l) HER2 staining; (m)–(p) EGFR staining; (q)–(t) CK5 staining. Each column represents a distinct molecular subtype. From left to right: luminal A (case 13—RE: positive, RP: positive, HER2: negative, EGFR: negative, and CK5: positive). Luminal B (case 21—RE: positive, RP: positive, HER2: positive, EGFR: negative, and CK5: positive), HER2 (case 20—RE: negative, RP: negative, HER2: positive, EGFR: negative, and CK5: negative), and basal-like (case 17—RE: negative, RP: negative, HER2: negative, EGFR: positive, and CK5: positive). Advance HRP visualization method streptavidin-biotin complex method. Mayer’s hematoxylin counterstain Bar: 25  𝜇 m.